Axa’s Revelation Biosciences REVB Stock Holding History

Axa’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10	Closed	-$27.5K	–	1107
2023 Q4	$27.5K	Hold	10	–	–	﹤0.01%	1055
2023 Q3	$38.6K	Hold	10	–	–	﹤0.01%	1049
2023 Q2	$52.6K	Hold	10	–	–	﹤0.01%	1064
2023 Q1	$72.8K	Hold	10	–	–	﹤0.01%	1085
2022 Q4	$372K	Hold	10	–	–	﹤0.01%	1024
2022 Q3	$512K	Hold	10	–	–	﹤0.01%	962
2022 Q2	$2.17M	Hold	10	–	–	0.01%	758
2022 Q1	$2.23M	Buy	+10	New	+$6.38M	0.01%	810

Other funds holding REVB

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PIS

POM Investment Strategies Raleigh, North Carolina $88.3M AUM 15.23% 1-Year Est. Return

Axa's REVB Position: Q1 2024 in Review

Axa sold out of Revelation Biosciences (REVB) in Q1 2024, closing a stake of 10 shares — an estimated $27.5K sold.

Axa first reported a position in REVB in Q1 2022 and held it in 8 quarters. The position peaked at $2.23M in Q1 2022. 3 funds tracked by Wall St. Rank hold REVB as of Q1 2024.

Axa reported no remaining Revelation Biosciences position as of Q1 2024 after selling out during the quarter.
Axa sold 10 Revelation Biosciences shares in Q1 2024, an estimated $27.5K.
Axa first reported a position in Revelation Biosciences in Q1 2022 and held it in 8 quarters.
Axa's Revelation Biosciences position peaked at $2.23M in Q1 2022.
3 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2024.

Based on Axa's 13F filing for Q1 2024, filed 15 May 2024.